Journal of Applied Toxicology · Jan 26, 2026

Embryotoxic and Oxidative Impact of Dapagliflozin: A Dose-Dependent Study Using a Chick Embryo Model

By Malik F, Perveen S, Haider I et al.

The teratogenic potential of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, widely used in managing type 2 diabetes, remains poorly characterized. This study investigates the dose-dependent developmental effects of dapagliflozin using a chick embryo model to provide critical insights into its safety during early developmental stages. Fertilized eggs were incubated under controlled conditions, and dapagliflozin was administered at concentrations of 1.0-2.5 mg/mL on embryonic Day 3. Morphometric analysis revealed significant reductions in body weight (up to 47%) in higher-dose groups compared to controls, with survival rates declining sharply (40% mortality) in the 2.5 mg/mL group. Histological examination demonstrated hepatic steatosis, pulmonary emphysema, and cardiac inflammation, alongside neural apoptosis and vascular abnormalities. Reactive oxygen species (ROS) levels, measured via DPPH (2,2-diphenyl-1-picrylhydrazyl), superoxide dismutase (SOD), and chloramphenicol acetyltransferase (CAT) assays, results from DPPH assay showed up to 94.7% of radical scavenging activity in heart tissue, while intracellular oxidative stress is confirmed by SOD and CAT assays, implicating oxidative stress as a central mediator of these abnormalities. This study provides the first comprehensive evidence of dapagliflozin's dose-dependent teratogenicity in a nonmammalian vertebrate model. The findings underscore the need for caution in prescribing dapagliflozin during pregnancy and warrant further investigations in mammalian systems to evaluate its potential implications for human health.

doi.org/10.1002/jat.70073PubMed 41588738Interventions

AgingResearch.News